Roche American Seragon purchase for $ 725 million

The Roche Switzerland hit the acquisition of Seragon Pharmaceuticals, biotechnology company headquartered in San Diego, in the United States. The transaction involves a cash payment of $ 725 million plus additional payments contingent of up to $ 1 billion, depending on some conditions.
The operation, which will strengthen the area of Oncology of the European Group, should be completed in the third quarter of this year and still needs the approval of regulatory authorities.
Once completed the deal, the portfolio of Seragon will be integrated Genentech Research Roche subsidiary headquartered in California.